Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bIRV BB
- Development stage
- Unknown
- Lead developer
- Pfizer
- Modality
- mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
**bIRV BB** is an investigational bivalent nucleoside-modified messenger RNA influenza vaccine developed by Pfizer and BioNTech. It contains modified RNA vaccine components encoding two influenza B strains and is intended to induce protective immune responses against influenza B virus. It was evaluated as part of Pfizer's Phase 1/2 influenza modRNA vaccine study in healthy adults.
- Other names
- bivalent influenza modRNA vaccine encoding 2 B strains
02
Targets
HA (Hemagglutinin)
Beyond the preview
Go deeper on bIRV BB.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bIRV BB.